Pub Date : 2024-01-14DOI: 10.21608/resoncol.2023.236479.1201
Ahmed Abd-Elhafeez, Mohamed Hassan, D. Almeldin, K. Abbas, Basel Abdelazeem, Mina Saba, Esraa Ahmed, K. Shohdy, L. Kassem
Background: Administration of trastuzumab (TRA) in resource-limited settings (RLS) is associated with significant deviations from per-label recommendations such as fixed-dose instead of weight-based, interruptions, and a reduced number of cycles. The impact of these deviations on the clinical outcomes of HER2-positive non-metastatic breast cancer is unclear. Methods: We retrospectively reviewed the records of patients with operable HER2-positive breast cancer treated at our center from 2013 to 2018 for TRA dose deviations. The standard protocol for TRA administration includes a one-year course of TRA with one intravenous dose every three weeks for 17 cycles. We assessed the number of cycles, underdosing based on body weight calculation, and low relative dose intensity (RDI). Cox regression analysis was used to identify predictors of survival and was adjusted for baseline clinical variables. Results: This analysis included 208 patients with a median age of 45 years. A total of 175 (84%) patients showed at least one per label deviation. Fifty-four patients (26%) were underdosed with a mean maintenance dose defect of 54 ±107 mg, 64 (31%) received a redu ced number of courses (≤ 9 cycles), and 103 patients (49.5%) received TRA at low RDI. Reduced number of cycles was the only factor associated with a worse hazard of recurrence-free survival and overall survival (HR: 2.25, 95% CI: 1.35 – 3.75, adjusted p =0.002) and (HR: 2.48, 95% CI: 1.36-4.52, adjusted p =0.003), respectively. Conclusion: In our cohort, not all the deviations had adverse impacts on clinical outcomes. Only a reduced number of cycles was associated with a worse recurrence-free and overall survival hazard. Improving access to anti-HER2 therapies in RLS is crucial. Ensuring the full course of TRA in RLS is needed.
{"title":"The Impact of Trastuzumab Administration Patterns on the Long-Term Clinical Outcomes of Patients with Non-Metastatic Breast Cancer in a Resource-Limited Setting","authors":"Ahmed Abd-Elhafeez, Mohamed Hassan, D. Almeldin, K. Abbas, Basel Abdelazeem, Mina Saba, Esraa Ahmed, K. Shohdy, L. Kassem","doi":"10.21608/resoncol.2023.236479.1201","DOIUrl":"https://doi.org/10.21608/resoncol.2023.236479.1201","url":null,"abstract":"Background: Administration of trastuzumab (TRA) in resource-limited settings (RLS) is associated with significant deviations from per-label recommendations such as fixed-dose instead of weight-based, interruptions, and a reduced number of cycles. The impact of these deviations on the clinical outcomes of HER2-positive non-metastatic breast cancer is unclear. Methods: We retrospectively reviewed the records of patients with operable HER2-positive breast cancer treated at our center from 2013 to 2018 for TRA dose deviations. The standard protocol for TRA administration includes a one-year course of TRA with one intravenous dose every three weeks for 17 cycles. We assessed the number of cycles, underdosing based on body weight calculation, and low relative dose intensity (RDI). Cox regression analysis was used to identify predictors of survival and was adjusted for baseline clinical variables. Results: This analysis included 208 patients with a median age of 45 years. A total of 175 (84%) patients showed at least one per label deviation. Fifty-four patients (26%) were underdosed with a mean maintenance dose defect of 54 ±107 mg, 64 (31%) received a redu ced number of courses (≤ 9 cycles), and 103 patients (49.5%) received TRA at low RDI. Reduced number of cycles was the only factor associated with a worse hazard of recurrence-free survival and overall survival (HR: 2.25, 95% CI: 1.35 – 3.75, adjusted p =0.002) and (HR: 2.48, 95% CI: 1.36-4.52, adjusted p =0.003), respectively. Conclusion: In our cohort, not all the deviations had adverse impacts on clinical outcomes. Only a reduced number of cycles was associated with a worse recurrence-free and overall survival hazard. Improving access to anti-HER2 therapies in RLS is crucial. Ensuring the full course of TRA in RLS is needed.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-18DOI: 10.21608/resoncol.2023.213783.1197
Suzan Talaat, Farah Farah
Background: Meningiomas, the most common primary central nervous system (CNS) tumors, include 15 distinct subtypes reflecting its broad morphological spectrum. Most subtypes have a benign clinical course and correspond to CNS World Health Organization (WHO) grade I. Chordoid meningiomas are a rare subtype (0.5% of all meningiomas) with relatively aggressive behavior and are classified as WHO grade II. Case presentation: We present a case of a 20-year-old man who presented to the emergency room with convulsions. A right parietal cerebral mass with peritumoral edema and a significant mass effect was discovered by magnetic resonance imaging. There was no systemic manifestations and hematological tests were normal. He underwent surgery and a histopathological examination of the excised tumor revealed the diagnosis of chordoid meningioma, WHO grade II. In addition, there was dense lymphocytic infiltration forming lymphoid follicles. Conclusion: Chordoid meningioma may be associated with extensive lymphoid infiltration with follicle formation in the absence of systemic or hematologic manifestations.
{"title":"Chordoid Meningioma with Extensive Lymphocytic Infiltration Forming Lymphoid Follicles: A Case Report","authors":"Suzan Talaat, Farah Farah","doi":"10.21608/resoncol.2023.213783.1197","DOIUrl":"https://doi.org/10.21608/resoncol.2023.213783.1197","url":null,"abstract":"Background: Meningiomas, the most common primary central nervous system (CNS) tumors, include 15 distinct subtypes reflecting its broad morphological spectrum. Most subtypes have a benign clinical course and correspond to CNS World Health Organization (WHO) grade I. Chordoid meningiomas are a rare subtype (0.5% of all meningiomas) with relatively aggressive behavior and are classified as WHO grade II. Case presentation: We present a case of a 20-year-old man who presented to the emergency room with convulsions. A right parietal cerebral mass with peritumoral edema and a significant mass effect was discovered by magnetic resonance imaging. There was no systemic manifestations and hematological tests were normal. He underwent surgery and a histopathological examination of the excised tumor revealed the diagnosis of chordoid meningioma, WHO grade II. In addition, there was dense lymphocytic infiltration forming lymphoid follicles. Conclusion: Chordoid meningioma may be associated with extensive lymphoid infiltration with follicle formation in the absence of systemic or hematologic manifestations.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135209667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-15DOI: 10.21608/resoncol.2023.186707.1190
Y. Moodley, S. Mashele
Background: Colorectal cancer (CRC) is amongst the most important cancers in resource-constrained South Africa. It is crucial that setting-specific research be conducted which seeks to answer questions around the feasibility of emerging treatment modalities for CRC in South Africa, as well as the subsequent clinical outcomes in patients receiving these treatments. Aim: To determine the status of CRC clinical trials in South Africa and identify areas in which CRC clinical trials need strengthening in this setting. Methods: A search of ClinTrials.gov, the Pan-African Clinical Trials Registry, and PubMed was performed to identify clinical trials of CRC in South Africa. Information on each clinical trial was collected and analyzed with descriptive statistics. Results: There were very few registered clinical trials on CRC in South Africa (n=20). Most studies were already completed at the time of this analysis (n=16, 80%), and were international multicenter studies on which South African research sites contributed data (n=19, 95%). Phase III trials were common (n=19, 95%), particularly those investigating pharmaceutical drugs (n=15, 75%). Most studies were funded by medical or pharmaceutical companies (n=12, 60%). Conclusion: The dearth of CRC clinical trials in South Africa must be addressed. This could primarily be achieved through local capacity development in clinical oncology and research methods.
{"title":"Clinical Trials on Colorectal Cancer in South Africa","authors":"Y. Moodley, S. Mashele","doi":"10.21608/resoncol.2023.186707.1190","DOIUrl":"https://doi.org/10.21608/resoncol.2023.186707.1190","url":null,"abstract":"Background: Colorectal cancer (CRC) is amongst the most important cancers in resource-constrained South Africa. It is crucial that setting-specific research be conducted which seeks to answer questions around the feasibility of emerging treatment modalities for CRC in South Africa, as well as the subsequent clinical outcomes in patients receiving these treatments. Aim: To determine the status of CRC clinical trials in South Africa and identify areas in which CRC clinical trials need strengthening in this setting. Methods: A search of ClinTrials.gov, the Pan-African Clinical Trials Registry, and PubMed was performed to identify clinical trials of CRC in South Africa. Information on each clinical trial was collected and analyzed with descriptive statistics. Results: There were very few registered clinical trials on CRC in South Africa (n=20). Most studies were already completed at the time of this analysis (n=16, 80%), and were international multicenter studies on which South African research sites contributed data (n=19, 95%). Phase III trials were common (n=19, 95%), particularly those investigating pharmaceutical drugs (n=15, 75%). Most studies were funded by medical or pharmaceutical companies (n=12, 60%). Conclusion: The dearth of CRC clinical trials in South Africa must be addressed. This could primarily be achieved through local capacity development in clinical oncology and research methods.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44792228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-16DOI: 10.21608/resoncol.2023.173693.1180
A. Mahmoud, E. Metwally, R. Balata, Amira Al-Amir Khater, Rania A Abdullah, Fouad Abutaleb
{"title":"The Influence of Serum Leptin Level and Body Mass Index on the Prognosis of Patients with Diffuse Large B Cell Lymphoma","authors":"A. Mahmoud, E. Metwally, R. Balata, Amira Al-Amir Khater, Rania A Abdullah, Fouad Abutaleb","doi":"10.21608/resoncol.2023.173693.1180","DOIUrl":"https://doi.org/10.21608/resoncol.2023.173693.1180","url":null,"abstract":"","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68553941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-10DOI: 10.21608/resoncol.2023.179779.1187
Y. Shaaban, S. El-Ashwah, A. Elshamy, M. Atef, M. Saafan, Ahmed E. Eladl, S. El-Sherpiny, Shaimaa Hendawy, Aya Elbogdady, Mohamed El Bogdady, B. Atef
Background: Castleman disease (CD) is a rare disorder that affects lymph nodes and has a wide range of associated symptoms. The affected lymph nodes show characteristic histological picture. Most of the unicentric Castleman disease (UCD) cases can be cured by complete surgical removal or radiotherapy, while multicentric CD (MCD) is much more complicated and have several subtypes and requires more effort to reach a precise diagnosis and management
{"title":"Multicentric vs. Unresectable Unicentric Castleman Disease with Active Presentation: An Orphan Rare Disease in a Young Egyptian Female Patient. A Case Report","authors":"Y. Shaaban, S. El-Ashwah, A. Elshamy, M. Atef, M. Saafan, Ahmed E. Eladl, S. El-Sherpiny, Shaimaa Hendawy, Aya Elbogdady, Mohamed El Bogdady, B. Atef","doi":"10.21608/resoncol.2023.179779.1187","DOIUrl":"https://doi.org/10.21608/resoncol.2023.179779.1187","url":null,"abstract":"Background: Castleman disease (CD) is a rare disorder that affects lymph nodes and has a wide range of associated symptoms. The affected lymph nodes show characteristic histological picture. Most of the unicentric Castleman disease (UCD) cases can be cured by complete surgical removal or radiotherapy, while multicentric CD (MCD) is much more complicated and have several subtypes and requires more effort to reach a precise diagnosis and management","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47456762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.21608/resoncol.2022.167065.1176
R. Alghandour, S. El-Ashwah, Z. Emarah, Salma Elashwah, Layla'M Saleh, Marwa O Elmaria, Mohamed A. Ebrahim, T. Elkhodary, Gehad A. Saleh, Nada F. El-Sheltawy, H. Zaki, S. Shamaa
Background: During the COVID ‐ 19 pandemic, there was limited data about the appropriate management of acute myeloid leukemia (AML) with COVID-19 infection and the possible post-COVID-19 complications reported in acute leukemia patients. Case presentation: We report a 52-year-old lady with AML and confirmed twice SARS-CoV-2 infection. The first infection was just after the diagnosis of AML before the administration of induction therapy, and the second infection was just after she received the salvage therapy. The COVID-19 infection was confirmed by qRT-PCR and high-resolution non-contrast computerized tomography of the chest. Unfortunately, the patient developed post-covid neurological complications, disturbed consciousness level, and encephalopathy. The COVID-19 infection may have triggered encephalopathy or exaggerated the neurological toxicity of cytarabine even in a small dose. Another possible explanation is the exaggeration of cytokine storm by the administration of granulocyte-stimulating factors used in salvage therapy. Conclusion: Management of COVID-19 infection in AML patients faces many challenges. These patients are more vulnerable and susceptible to many complications and high mortality rates. The treatment approach needs to be tailored to overcome the interaction between the treatment adverse events and the biology of covid-19 infection.
{"title":"A Diagnostic Dilemma of Encephalopathy in Acute Myeloid Leukemia Patient with Twice COVID-19 Infection: A Case Report","authors":"R. Alghandour, S. El-Ashwah, Z. Emarah, Salma Elashwah, Layla'M Saleh, Marwa O Elmaria, Mohamed A. Ebrahim, T. Elkhodary, Gehad A. Saleh, Nada F. El-Sheltawy, H. Zaki, S. Shamaa","doi":"10.21608/resoncol.2022.167065.1176","DOIUrl":"https://doi.org/10.21608/resoncol.2022.167065.1176","url":null,"abstract":"Background: During the COVID ‐ 19 pandemic, there was limited data about the appropriate management of acute myeloid leukemia (AML) with COVID-19 infection and the possible post-COVID-19 complications reported in acute leukemia patients. Case presentation: We report a 52-year-old lady with AML and confirmed twice SARS-CoV-2 infection. The first infection was just after the diagnosis of AML before the administration of induction therapy, and the second infection was just after she received the salvage therapy. The COVID-19 infection was confirmed by qRT-PCR and high-resolution non-contrast computerized tomography of the chest. Unfortunately, the patient developed post-covid neurological complications, disturbed consciousness level, and encephalopathy. The COVID-19 infection may have triggered encephalopathy or exaggerated the neurological toxicity of cytarabine even in a small dose. Another possible explanation is the exaggeration of cytokine storm by the administration of granulocyte-stimulating factors used in salvage therapy. Conclusion: Management of COVID-19 infection in AML patients faces many challenges. These patients are more vulnerable and susceptible to many complications and high mortality rates. The treatment approach needs to be tailored to overcome the interaction between the treatment adverse events and the biology of covid-19 infection.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41603365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-19DOI: 10.21608/resoncol.2022.135734.1166
Elia Hakim, Amina Mostafa, M. Mohamed, M. Sherif, Maha El Naggar
Background: Tumor-infiltrating lymphocytes (TILs) were found to be associated with a better clinical outcome in specific subtypes of breast cancer. Aim: To study the association between TILs and the prognosis of Egyptian patients with HER2-negative breast cancer metastatic to the viscera. Methods: This prospective study included 100 patients with HER2-negative metastatic breast cancer. Intratumoral TILs, stromal TILs, and CD4 and CD8 were examined in the pathological specimens and their relationship with survival and response to treatment was studied. Results: At a median follow-up period of 43 months, the median overall survival was 44.7 months (95%CI: 39.2-50.2) and the 5-year overall survival rate was 28%. A high level of CD8+ve TILs was associated with significantly longer overall survival (p<0.001) and progression-free survival (p=0.043). There was no significant correlation between intratumoral TILs, stromal TILs, or CD4+ve and overall survival. Conclusions: A higher level of CD8+ve TILs is associated with better overall as well as progression-free survival in HER2-negative breast cancer with visceral metastases.
{"title":"Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases","authors":"Elia Hakim, Amina Mostafa, M. Mohamed, M. Sherif, Maha El Naggar","doi":"10.21608/resoncol.2022.135734.1166","DOIUrl":"https://doi.org/10.21608/resoncol.2022.135734.1166","url":null,"abstract":"Background: Tumor-infiltrating lymphocytes (TILs) were found to be associated with a better clinical outcome in specific subtypes of breast cancer. Aim: To study the association between TILs and the prognosis of Egyptian patients with HER2-negative breast cancer metastatic to the viscera. Methods: This prospective study included 100 patients with HER2-negative metastatic breast cancer. Intratumoral TILs, stromal TILs, and CD4 and CD8 were examined in the pathological specimens and their relationship with survival and response to treatment was studied. Results: At a median follow-up period of 43 months, the median overall survival was 44.7 months (95%CI: 39.2-50.2) and the 5-year overall survival rate was 28%. A high level of CD8+ve TILs was associated with significantly longer overall survival (p<0.001) and progression-free survival (p=0.043). There was no significant correlation between intratumoral TILs, stromal TILs, or CD4+ve and overall survival. Conclusions: A higher level of CD8+ve TILs is associated with better overall as well as progression-free survival in HER2-negative breast cancer with visceral metastases.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42780076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-23DOI: 10.21608/resoncol.2022.136368.1167
M. Hafez, A. Zaki, Osama Bahy, Amir M. Zaid, Mohamed ElAreeny, Merit ElMaadawy, S. Awny
Background: Cervical lymph node metastasis is a prognostic factor in papillary thyroid carcinoma (PTC). Metastasizing PTC to cervical lymph nodes is very common and occurs in 30-80% of patients. Aim: To investigate the risk factors of skip lateral lymph node metastasis in PTC patients. Methods: This retrospective study was conducted at a single institution and included PTC patients treated in the period between 2018 and 2021. All patients with PTC who underwent total thyroidectomy with central and lateral block neck dissection were reviewed for skip metastases which was confirmed by histopathologic examination. Results: During the study period, 267 patients with PTC underwent total thyroidectomy with central and/or lateral block neck dissection. Among them, only 64 patients matched the study inclusion criteria and their pathology was reviewed for skip metastases. Thirteen (20.3%) patients showed skip metastases. Their mean (±SD) age was 50.1 (±16.7) years and 8 (61.5%) were females. Only age ≥40 years and tumor size ≤ 0.5 cm differed significantly between patients with skip metastasis and those without. Conclusions: The results support the conduction of a prospective multi-centric study with a larger sample size to better understand the risk factors for developing skip metastasis in PTC. This would help in selecting patients with a risk for skip metastasis. bilaterality, multifocality, presence of psammoma bodies, tumor site and size, capsular invasion, extrathyroid extension, number of harvested central LNs and number of harvested/metastatic lateral LNs.
{"title":"Skip Metastasis in Papillary Thyroid Cancer: Is it Predictable?","authors":"M. Hafez, A. Zaki, Osama Bahy, Amir M. Zaid, Mohamed ElAreeny, Merit ElMaadawy, S. Awny","doi":"10.21608/resoncol.2022.136368.1167","DOIUrl":"https://doi.org/10.21608/resoncol.2022.136368.1167","url":null,"abstract":"Background: Cervical lymph node metastasis is a prognostic factor in papillary thyroid carcinoma (PTC). Metastasizing PTC to cervical lymph nodes is very common and occurs in 30-80% of patients. Aim: To investigate the risk factors of skip lateral lymph node metastasis in PTC patients. Methods: This retrospective study was conducted at a single institution and included PTC patients treated in the period between 2018 and 2021. All patients with PTC who underwent total thyroidectomy with central and lateral block neck dissection were reviewed for skip metastases which was confirmed by histopathologic examination. Results: During the study period, 267 patients with PTC underwent total thyroidectomy with central and/or lateral block neck dissection. Among them, only 64 patients matched the study inclusion criteria and their pathology was reviewed for skip metastases. Thirteen (20.3%) patients showed skip metastases. Their mean (±SD) age was 50.1 (±16.7) years and 8 (61.5%) were females. Only age ≥40 years and tumor size ≤ 0.5 cm differed significantly between patients with skip metastasis and those without. Conclusions: The results support the conduction of a prospective multi-centric study with a larger sample size to better understand the risk factors for developing skip metastasis in PTC. This would help in selecting patients with a risk for skip metastasis. bilaterality, multifocality, presence of psammoma bodies, tumor site and size, capsular invasion, extrathyroid extension, number of harvested central LNs and number of harvested/metastatic lateral LNs.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42293655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-19DOI: 10.21608/resoncol.2022.148102.1171
M. Mohammed, N. Ahmed
Background: Placental mesenchymal dysplasia (PMD) is a rare placental disease of poorly understood etiology. It is characterized by aneurysmal dilatation of the chorionic blood vessels, mesenchymal proliferation, and myxomatous degeneration of the stem villi. Although it shares radiological and gross pathological features with partial hydatidiform mole, PMD doesn't necessitate termination of pregnancy. Case presentation: A 20-year-old woman presented at 25 weeks of gestation with profuse vaginal bleeding and loss of sensation of fetal movements. Abdominal ultrasound revealed a dead fetus and a markedly thick placenta which contains frequent hypoechoic cystic spaces creating a Swiss cheese appearance. Serum β -HCG was within the normal range as regards the gestational stage. A gross examination of the placenta revealed dilated tortuous blood vessels with frequent aneurysms on the placental surface and the cut section showed clotted blood. No definite vesicles were seen. Histopathological evaluation of the placental tissue revealed a mixture of normal and dilated villi with thick chorionic blood vessels and myxomatous degeneration of the villous cores. There was no trophoblastic proliferation, features were kept with PMD. Conclusion: Placental mesenchymal dysplasia is a rare placental disease that is usually confused with partial hydatidiform mole at both radiological and gross pathological features. However, histopathological examination helps in adopting an accurate diagnosis.
{"title":"Placental Mesenchymal Dysplasia: A Confusing Entity and the Definitive Role of Histopathology","authors":"M. Mohammed, N. Ahmed","doi":"10.21608/resoncol.2022.148102.1171","DOIUrl":"https://doi.org/10.21608/resoncol.2022.148102.1171","url":null,"abstract":"Background: Placental mesenchymal dysplasia (PMD) is a rare placental disease of poorly understood etiology. It is characterized by aneurysmal dilatation of the chorionic blood vessels, mesenchymal proliferation, and myxomatous degeneration of the stem villi. Although it shares radiological and gross pathological features with partial hydatidiform mole, PMD doesn't necessitate termination of pregnancy. Case presentation: A 20-year-old woman presented at 25 weeks of gestation with profuse vaginal bleeding and loss of sensation of fetal movements. Abdominal ultrasound revealed a dead fetus and a markedly thick placenta which contains frequent hypoechoic cystic spaces creating a Swiss cheese appearance. Serum β -HCG was within the normal range as regards the gestational stage. A gross examination of the placenta revealed dilated tortuous blood vessels with frequent aneurysms on the placental surface and the cut section showed clotted blood. No definite vesicles were seen. Histopathological evaluation of the placental tissue revealed a mixture of normal and dilated villi with thick chorionic blood vessels and myxomatous degeneration of the villous cores. There was no trophoblastic proliferation, features were kept with PMD. Conclusion: Placental mesenchymal dysplasia is a rare placental disease that is usually confused with partial hydatidiform mole at both radiological and gross pathological features. However, histopathological examination helps in adopting an accurate diagnosis.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47396611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-11DOI: 10.21608/resoncol.2021.82375.1147
A. Ali, Amira M. El-Hefedy, D. Sayed, A. Osman
Background: Remarkable progress has been made in the treatment of pediatric acute lymphoblastic leukemia (ALL), with survival rates reaching > 80% in high-income countries. In Egypt, the outcome of treatment of ALL has been less favorable. Aim: To evaluate the clinicolaboratory characteristics in patients admitted at Sohag Cancer Center and to assess the outcome and the prognostic factors affecting it. Methods: This retrospective study included 79 pediatric ALL patients, from January 2010 to December 2014, who were treated according to modified Total therapy study XIIIB high-risk ALL of St. Jude Children's Research Hospital (SJCRH). Results: 52% were males with a median age of 6 years. 58.2% were stratified as HR, 69.6% had precursor B-ALL, 39.2% presented with t otal leucocytic count (TLC) (≥ 50x109/L), and 11.3% had CNS leukemia. Complete remission (CR) was achieved in 87.3%. Regarding treatment outcome, induction failure was reported in 5.1%, relapse in 24.1%, deaths in CR in 7.2%, and continuous complete remission in 59.5%. The median follow-up was 42 months, 4 years OS, EFS, and DFS were 64.1 ± 5.6, 57 ± 5.7, and 63.3 ± 5.8% respectively. TLC and bone marrow aspirate postinduction were the only significant prognostic factors affecting EFS. Conclusions: The modified TXIIIB of SJCRH was effective in improving ALL outcomes in our center, however, survival rates were much lower than internationally reported results with only initial TLC and response postinduction having a significant effect on EFS and DFS.
{"title":"Clinicolaboratory Characteristics and Outcome of Pediatric Acute Lymphoblastic Leukemia in a Resource-Limited Setting: A Study from South Egypt","authors":"A. Ali, Amira M. El-Hefedy, D. Sayed, A. Osman","doi":"10.21608/resoncol.2021.82375.1147","DOIUrl":"https://doi.org/10.21608/resoncol.2021.82375.1147","url":null,"abstract":"Background: Remarkable progress has been made in the treatment of pediatric acute lymphoblastic leukemia (ALL), with survival rates reaching > 80% in high-income countries. In Egypt, the outcome of treatment of ALL has been less favorable. Aim: To evaluate the clinicolaboratory characteristics in patients admitted at Sohag Cancer Center and to assess the outcome and the prognostic factors affecting it. Methods: This retrospective study included 79 pediatric ALL patients, from January 2010 to December 2014, who were treated according to modified Total therapy study XIIIB high-risk ALL of St. Jude Children's Research Hospital (SJCRH). Results: 52% were males with a median age of 6 years. 58.2% were stratified as HR, 69.6% had precursor B-ALL, 39.2% presented with t otal leucocytic count (TLC) (≥ 50x109/L), and 11.3% had CNS leukemia. Complete remission (CR) was achieved in 87.3%. Regarding treatment outcome, induction failure was reported in 5.1%, relapse in 24.1%, deaths in CR in 7.2%, and continuous complete remission in 59.5%. The median follow-up was 42 months, 4 years OS, EFS, and DFS were 64.1 ± 5.6, 57 ± 5.7, and 63.3 ± 5.8% respectively. TLC and bone marrow aspirate postinduction were the only significant prognostic factors affecting EFS. Conclusions: The modified TXIIIB of SJCRH was effective in improving ALL outcomes in our center, however, survival rates were much lower than internationally reported results with only initial TLC and response postinduction having a significant effect on EFS and DFS.","PeriodicalId":33915,"journal":{"name":"Research in Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48101714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：